SI3527263T1 - Derivati bipirazola kot zaviralci JAK - Google Patents

Derivati bipirazola kot zaviralci JAK

Info

Publication number
SI3527263T1
SI3527263T1 SI201431754T SI201431754T SI3527263T1 SI 3527263 T1 SI3527263 T1 SI 3527263T1 SI 201431754 T SI201431754 T SI 201431754T SI 201431754 T SI201431754 T SI 201431754T SI 3527263 T1 SI3527263 T1 SI 3527263T1
Authority
SI
Slovenia
Prior art keywords
jak inhibitors
bipyrazole derivatives
bipyrazole
derivatives
jak
Prior art date
Application number
SI201431754T
Other languages
English (en)
Slovenian (sl)
Inventor
Yun-Long Li
Jincong Zhuo
Ding-Quan Qian
Song Mei
Ganfeng Cao
Yongchun Pan
Qun Li
Zhongjiang Jia
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of SI3527263T1 publication Critical patent/SI3527263T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI201431754T 2013-05-17 2014-05-16 Derivati bipirazola kot zaviralci JAK SI3527263T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361824683P 2013-05-17 2013-05-17
EP18215671.1A EP3527263B1 (en) 2013-05-17 2014-05-16 Bipyrazole derivatives as jak inhibitors

Publications (1)

Publication Number Publication Date
SI3527263T1 true SI3527263T1 (sl) 2021-05-31

Family

ID=50983151

Family Applications (5)

Application Number Title Priority Date Filing Date
SI201432117T SI4275756T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot zaviralci jak
SI201431754T SI3527263T1 (sl) 2013-05-17 2014-05-16 Derivati bipirazola kot zaviralci JAK
SI201431118T SI3231801T1 (sl) 2013-05-17 2014-05-16 Bipirazolna sol kot inhibitor JAK
SI201430239A SI2997023T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot inhibitorji JAK
SI201432046T SI3786162T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot zaviralci JAK

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201432117T SI4275756T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot zaviralci jak

Family Applications After (3)

Application Number Title Priority Date Filing Date
SI201431118T SI3231801T1 (sl) 2013-05-17 2014-05-16 Bipirazolna sol kot inhibitor JAK
SI201430239A SI2997023T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot inhibitorji JAK
SI201432046T SI3786162T1 (sl) 2013-05-17 2014-05-16 Bipirazolni derivati kot zaviralci JAK

Country Status (36)

Country Link
US (8) US9382231B2 (enExample)
EP (6) EP3231801B1 (enExample)
JP (5) JP6415543B2 (enExample)
KR (4) KR102729910B1 (enExample)
CN (2) CN107698569B (enExample)
AR (2) AR096330A1 (enExample)
AU (5) AU2014265279B2 (enExample)
BR (1) BR112015028501B8 (enExample)
CA (1) CA2911536C (enExample)
CL (1) CL2015003355A1 (enExample)
CR (2) CR20190156A (enExample)
CY (3) CY1119105T1 (enExample)
DK (4) DK3231801T3 (enExample)
EA (2) EA039660B1 (enExample)
ES (5) ES3047826T3 (enExample)
FI (2) FI3786162T3 (enExample)
HK (1) HK1245769B (enExample)
HR (5) HRP20251220T1 (enExample)
HU (4) HUE053122T2 (enExample)
IL (4) IL242453B (enExample)
LT (5) LT3527263T (enExample)
ME (2) ME02763B (enExample)
MX (2) MX385187B (enExample)
MY (1) MY174788A (enExample)
PE (2) PE20200527A1 (enExample)
PH (2) PH12015502563B1 (enExample)
PL (4) PL3786162T3 (enExample)
PT (5) PT3786162T (enExample)
RS (5) RS64591B1 (enExample)
SG (2) SG10201709469SA (enExample)
SI (5) SI4275756T1 (enExample)
SM (5) SMT202300352T1 (enExample)
TR (1) TR201905814T4 (enExample)
TW (4) TWI664176B (enExample)
UA (1) UA117830C2 (enExample)
WO (1) WO2014186706A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1966202T1 (sl) 2005-12-13 2012-01-31 Incyte Corp S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
EP2173752B2 (en) 2007-06-13 2022-07-13 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CA2762174C (en) 2009-05-22 2018-02-20 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN106967070A (zh) 2009-05-22 2017-07-21 因塞特控股公叞 䜜䞺jak抑制剂的化合物
SG177384A1 (en) 2009-06-29 2012-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
EP3715347B1 (en) 2010-03-10 2021-12-22 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
NZ603686A (en) 2010-05-21 2014-11-28 Incyte Corp Topical formulation for a jak inhibitor
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
TWI577676B (zh) 2011-06-20 2017-04-11 英塞特控股公叞 䜜為抑制劑之吖䞁啶基苯基、吡啶基或吡基矧醯胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 䜜為抑制劑之環己基氮雜環䞁烷衍生物
PL3196202T3 (pl) 2011-09-02 2019-09-30 Incyte Holdings Corporation Heterocykloaminy jako inhibitory pi3k
UA111854C2 (uk) 2011-09-07 2016-06-24 ІМсайт ХПлЎіМгс КПрпПрейшМ СпПсПбО і прПЌіжМі спПлукО Ўля ПтрОЌаММя іМгібітПрів jak
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲抑制劑之哌啶基環䞁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
MX2015005428A (es) 2012-11-01 2015-07-21 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
JP6397831B2 (ja) 2013-03-06 2018-09-26 むンサむト・ホヌルディングス・コヌポレむション   阻害剀の補造方法及びその䞭間䜓
WO2014186706A1 (en) * 2013-05-17 2014-11-20 Incyte Corporation Bipyrazole derivatives as jak inhibitors
UA120499C2 (uk) 2013-08-07 2019-12-26 ІМсайт КПрпПрейшМ ЛікуваММя захвПрюваМь із застПсуваММяЌ лікарськОх фПрЌ з упПвільМеМОЌ вОвільМеММяЌ Ўля іМгібітПра jak1
PE20161388A1 (es) * 2014-02-28 2016-12-28 Incyte Corp Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos
NZ725778A (en) 2014-04-08 2023-04-28 Incyte Holdings Corp Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
JP2017514832A (ja) 2014-04-30 2017-06-08 むンサむト・コヌポレむション  抑制剀を調補する方法及びその新しい圢態
WO2015184305A1 (en) * 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
MD3831833T2 (ro) 2015-02-27 2023-04-30 Incyte Holdings Corp Procedee pentru prepararea unui inhibitor PI3K
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
CN107847432A (zh) 2015-05-29 2018-03-27 西執奈克西斯公叞 D2o皳定化的药物制剂
TWI744256B (zh) 2015-11-06 2021-11-01 矎商英塞特公叞 䜜為-γ抑制劑之雜環化合物
AR107293A1 (es) 2016-01-05 2018-04-18 Incyte Corp COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
CN107759623B (zh) * 2016-08-23 2020-08-14 苏州旺山旺氎生物医药有限公叞 Jak抑制剂的䞭闎䜓及其制倇方法
MX2019002627A (es) * 2016-09-06 2019-10-30 Hoffmann La Roche Compuestos de 8-(azetidin-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de uso del mismo.
MD3697789T2 (ro) 2017-10-18 2022-02-28 Incyte Corp Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MD3746429T2 (ro) 2018-01-30 2022-08-31 Incyte Corp Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
BR112020016628A2 (pt) 2018-02-16 2020-12-15 Incyte Corporation Inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
HUE067471T2 (hu) * 2018-03-30 2024-10-28 Incyte Corp Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
CN112567247A (zh) 2018-04-13 2021-03-26 因赛特公叞 甚于移怍物抗宿䞻病的生物标志物
CN108484468A (zh) * 2018-05-11 2018-09-04 南京倧孊 芳基氮杂环䞁烷类化合物的制倇方法
CA3101323A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
IL282643B2 (en) 2018-10-31 2025-08-01 Incyte Corp A selective jak1 inhibitor for use in a method of treating hematological disease
AU2019403304B2 (en) 2018-12-19 2025-09-04 Incyte Corporation JAK1 pathway inhibitors for the treatment of gastrointestinal disease
JP2022524997A (ja) 2019-03-05 2022-05-11 むンサむト・コヌポレむション 慢性肺同皮移怍片機胜䞍党の治療のための経路阻害剀
JP2022526301A (ja) * 2019-03-19 2022-05-24 むンサむト・コヌポレむション 尋垞性癜斑のバむオマヌカヌ
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・むンコヌポレむテッド 骚髄線維症および関連状態を凊眮するための方法
US12203942B2 (en) 2019-10-10 2025-01-21 Incyte Corporation Biomarkers for graft-versus-host disease
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
JP7518900B2 (ja) * 2019-10-16 2024-07-18 むンサむト・コヌポレむション 皮膚゚リテマトヌデス及び扁平苔癬の治療のための阻害剀の䜿甚
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115836089A (zh) 2020-05-13 2023-03-21 迪斯克医药公叞 甚于治疗骚髓纀绎化的抗血幌玠hjv抗䜓
FI4157831T3 (fi) 2020-06-02 2024-12-02 Incyte Corp MenetelmiÀ jak1-estÀjÀn valmistamiseksi
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
IL300555A (en) 2020-08-18 2023-04-01 Incyte Corp Process and intermediates for preparing a JAK inhibitor
AU2021329301A1 (en) 2020-08-18 2023-04-13 Incyte Corporation Process and intermediates for preparing a JAK1 inhibitor
CN112159394B (zh) * 2020-10-09 2021-10-22 嘉兎特科眗生物科技有限公叞 䞀种䜜䞺jak激酶抑制剂的小分子化合物及其甚途
HRP20250528T1 (hr) 2020-12-04 2025-06-20 Incyte Corporation Jak inhibitor s analogom vitamina d za liječenje koşnih bolesti
US11957661B2 (en) * 2020-12-08 2024-04-16 Incyte Corporation JAK1 pathway inhibitors for the treatment of vitiligo
CN114099514A (zh) * 2020-12-29 2022-03-01 䞊海岞阔医药科技有限公叞 预防或治疗egfr功胜匂垞盞关的副䜜甚的方法
EP4274578A1 (en) 2021-01-11 2023-11-15 Incyte Corporation Combination therapy comprising jak pathway inhibitor and rock inhibitor
LT4333840T (lt) 2021-05-03 2026-01-12 Incyte Corporation Jak1 kelio inhibitoriai, skirti mazgelinio nieÅŸulio gydymui
US12071439B2 (en) 2021-07-12 2024-08-27 Incyte Corporation Process and intermediates for preparing a JAK inhibitor
CN119768166A (zh) 2022-08-05 2025-04-04 因赛特公叞 䜿甚jak抑制剂的荚麻疹治疗
WO2024192350A1 (en) 2023-03-16 2024-09-19 Incyte Corporation Jak1 pathway inhibitors for the treatment of asthma
CN117186078A (zh) * 2023-11-06 2023-12-08 药康䌗拓(北京)医药科技有限公叞 氘代氮杂环䞁烷类jak抑制剂药物及甚途
US20250325664A1 (en) 2024-04-22 2025-10-23 Incyte Corporation Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60106847U (ja) 1983-12-27 1985-07-20 富士重工業株匏䌚瀟 宀倖埌写鏡
JP2650681B2 (ja) 1987-07-10 1997-09-03 株匏䌚瀟ブリヂストン 空気ばね
JPH0515775Y2 (enExample) 1987-07-13 1993-04-26
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
HU230396B1 (hu) 2000-06-28 2016-04-28 Smithkline Beecham Plc Nedves őrlési eljárás
BR0212760A (pt) 2001-09-19 2004-12-07 Aventis Pharma Sa Compostos quìmicos
CA2462657C (en) 2001-10-30 2011-04-26 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2006056399A2 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
SI1966202T1 (sl) 2005-12-13 2012-01-31 Incyte Corp S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
EP2173752B2 (en) 2007-06-13 2022-07-13 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EA020777B1 (ru) * 2007-11-16 2015-01-30 ИМсайт КПрпПрейшМ 4-пОразПлОл-n-арОлпОрОЌОЎОМ-2-аЌОМы, 4-пОразПлОл-n-пОразПлОлпОрОЌОЎОМ-2-аЌОМы О 4-пОразПлОл-n-пОрОЎОлпОрОЌОЎОМ-2-аЌОМы в качестве ОМгОбОтПрПв кОМаз janus
AU2009223640B2 (en) * 2008-03-11 2013-07-04 Incyte Holdings Corporation Azetidine and cyclobutane derivatives as jak inhibitors
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثؚطات انزيم jak و المركؚات الوسيطة المتعلقة ØšÙ‡
CN106967070A (zh) 2009-05-22 2017-07-21 因塞特控股公叞 䜜䞺jak抑制剂的化合物
CA2762174C (en) 2009-05-22 2018-02-20 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
PL2486041T3 (pl) 2009-10-09 2014-01-31 Incyte Holdings Corp Pochodne hydroksylowe, keto i glukuronidowe 3-(4-(7H-pirolo[2,3-d]pirymidyn-4-ylo)-1H-pirazol-1-ilo)-3-cyklopentylopropanonitrylu
JP5858434B2 (ja) 2010-02-18 2016-02-10 むンサむト・ホヌルディングス・コヌポレむション   キナヌれ阻害薬ずしおのシクロブタンおよびメチルシクロブタン誘導䜓
EP3715347B1 (en) 2010-03-10 2021-12-22 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US8962596B2 (en) * 2010-04-14 2015-02-24 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases
NZ603686A (en) 2010-05-21 2014-11-28 Incyte Corp Topical formulation for a jak inhibitor
PE20140146A1 (es) * 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
JP5917544B2 (ja) 2010-11-19 2016-05-18 むンサむト・ホヌルディングス・コヌポレむション   阻害剀ずしおの耇玠環眮換ピロロピリゞンおよびピロロピリミゞン
US8828987B2 (en) * 2010-12-10 2014-09-09 Rottapharm Biotech S.R.L. Pyridine amide derivatives as EP4 receptor antagonists
WO2012116248A1 (en) 2011-02-24 2012-08-30 Massachusetts Institute Of Technology ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
TWI577676B (zh) 2011-06-20 2017-04-11 英塞特控股公叞 䜜為抑制劑之吖䞁啶基苯基、吡啶基或吡基矧醯胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 䜜為抑制劑之環己基氮雜環䞁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 ІМсайт ХПлЎіМгс КПрпПрейшМ СпПсПбО і прПЌіжМі спПлукО Ўля ПтрОЌаММя іМгібітПрів jak
EP2758377B1 (en) 2011-09-22 2017-08-02 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
TW201406761A (zh) * 2012-05-18 2014-02-16 Incyte Corp 做爲抑制劑之哌啶基環䞁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
MX2015005428A (es) 2012-11-01 2015-07-21 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
JP6397831B2 (ja) 2013-03-06 2018-09-26 むンサむト・ホヌルディングス・コヌポレむション   阻害剀の補造方法及びその䞭間䜓
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc م؎تقات سلفامويل ؚيرولاميد واستخدامها كادوية لمعالجة التهاؚ الكؚد نوع ØšÙŠ
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
SG11201509463YA (en) 2013-05-17 2015-12-30 Hoffmann La Roche 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
WO2014186706A1 (en) 2013-05-17 2014-11-20 Incyte Corporation Bipyrazole derivatives as jak inhibitors
UA120499C2 (uk) 2013-08-07 2019-12-26 ІМсайт КПрпПрейшМ ЛікуваММя захвПрюваМь із застПсуваММяЌ лікарськОх фПрЌ з упПвільМеМОЌ вОвільМеММяЌ Ўля іМгібітПра jak1
PE20161388A1 (es) 2014-02-28 2016-12-28 Incyte Corp Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos
JP2017514832A (ja) 2014-04-30 2017-06-08 むンサむト・コヌポレむション  抑制剀を調補する方法及びその新しい圢態
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
MA41185B1 (fr) 2014-12-16 2019-12-31 Novartis Ag Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc
BR112020016628A2 (pt) 2018-02-16 2020-12-15 Incyte Corporation Inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
FI4157831T3 (fi) 2020-06-02 2024-12-02 Incyte Corp MenetelmiÀ jak1-estÀjÀn valmistamiseksi
HRP20250528T1 (hr) 2020-12-04 2025-06-20 Incyte Corporation Jak inhibitor s analogom vitamina d za liječenje koşnih bolesti
US11957661B2 (en) 2020-12-08 2024-04-16 Incyte Corporation JAK1 pathway inhibitors for the treatment of vitiligo

Also Published As

Publication number Publication date
CA2911536C (en) 2021-07-20
HUE063817T2 (hu) 2024-01-28
EP3231801A1 (en) 2017-10-18
NZ753636A (en) 2020-11-27
US20230159501A1 (en) 2023-05-25
CL2015003355A1 (es) 2016-05-27
SMT202300352T1 (it) 2024-01-10
AU2018223058B2 (en) 2020-01-02
KR102442747B1 (ko) 2022-09-14
TW201940479A (zh) 2019-10-16
ME03355B (me) 2019-10-20
TW202432140A (zh) 2024-08-16
EP3786162B1 (en) 2023-08-09
EP3527263B1 (en) 2020-10-28
NZ753638A (en) 2020-11-27
EP2997023B9 (en) 2018-06-13
US9926301B2 (en) 2018-03-27
KR102663357B1 (ko) 2024-05-14
US11905275B2 (en) 2024-02-20
PT2997023T (pt) 2017-05-31
CY1119105T1 (el) 2018-02-14
JP2022163162A (ja) 2022-10-25
IL264409B (en) 2021-05-31
IL242453B (en) 2019-11-28
SG10201709469SA (en) 2017-12-28
EP3527263A1 (en) 2019-08-21
US9382231B2 (en) 2016-07-05
EP4620528A3 (en) 2025-11-26
KR102729910B1 (ko) 2024-11-15
AU2018223058A1 (en) 2018-09-20
IL282644B (en) 2021-10-31
LT3231801T (lt) 2019-08-12
CN107698569B (zh) 2020-11-27
MX385187B (es) 2025-03-14
AU2020202000B2 (en) 2021-03-11
AU2021202685B2 (en) 2022-11-17
LT3527263T (lt) 2021-05-10
JP6775560B2 (ja) 2020-10-28
EP3786162A1 (en) 2021-03-03
PE20160126A1 (es) 2016-02-24
EP4275756B1 (en) 2025-09-03
PL3527263T3 (pl) 2021-05-17
JP7126741B2 (ja) 2022-08-29
EP4275756A3 (en) 2024-02-07
BR112015028501A2 (pt) 2017-07-25
AU2020202000A1 (en) 2020-04-09
US20180312492A1 (en) 2018-11-01
BR112015028501B8 (pt) 2023-01-24
RS64591B1 (sr) 2023-10-31
US11591318B2 (en) 2023-02-28
EA202090291A3 (ru) 2020-06-30
US20160289215A1 (en) 2016-10-06
US20250206726A1 (en) 2025-06-26
PE20200527A1 (es) 2020-03-09
US10435392B2 (en) 2019-10-08
AU2021202685A1 (en) 2021-05-27
MX2015015738A (es) 2016-03-16
RS67392B1 (sr) 2025-11-28
EP3231801B1 (en) 2019-02-13
PH12015502563B1 (en) 2019-04-26
CN105452239A (zh) 2016-03-30
AU2022263454A1 (en) 2022-12-08
AU2014265279A1 (en) 2015-11-26
DK3786162T3 (da) 2023-10-09
RS56012B1 (sr) 2017-09-29
SI2997023T1 (sl) 2017-07-31
LT3786162T (lt) 2023-11-27
PL3231801T3 (pl) 2019-07-31
PL3786162T3 (pl) 2024-04-08
EP2997023A1 (en) 2016-03-23
TWI840646B (zh) 2024-05-01
US20200010456A1 (en) 2020-01-09
HUE033587T2 (hu) 2017-12-28
TW202116320A (zh) 2021-05-01
SMT201900223T1 (it) 2019-07-11
IL287313B (en) 2022-03-01
ES2960731T3 (es) 2024-03-06
HRP20251220T1 (hr) 2025-12-05
RS61482B1 (sr) 2021-03-31
AR118120A2 (es) 2021-09-22
CN105452239B (zh) 2017-11-21
TWI719401B (zh) 2021-02-21
US20240150327A1 (en) 2024-05-09
TWI885650B (zh) 2025-06-01
SI4275756T1 (sl) 2025-12-31
PT3231801T (pt) 2019-05-24
AU2014265279B2 (en) 2018-09-27
DK3527263T3 (da) 2021-01-25
JP2021008493A (ja) 2021-01-28
JP6415543B2 (ja) 2018-10-31
US20210238168A1 (en) 2021-08-05
DK3231801T3 (en) 2019-04-15
HUE053122T2 (hu) 2021-06-28
FI3786162T3 (fi) 2023-10-02
US12247020B2 (en) 2025-03-11
EA036448B1 (ru) 2020-11-11
CR20190156A (es) 2019-05-16
US20140343030A1 (en) 2014-11-20
CN107698569A (zh) 2018-02-16
CA2911536A1 (en) 2014-11-20
ES2626793T3 (es) 2017-07-26
HRP20190713T1 (hr) 2019-06-14
NZ753639A (en) 2020-11-27
SMT202100040T1 (it) 2021-03-15
SI3231801T1 (sl) 2019-05-31
PT4275756T (pt) 2025-10-31
US11001571B2 (en) 2021-05-11
EP4275756A2 (en) 2023-11-15
TW201512191A (zh) 2015-04-01
EA039660B1 (ru) 2022-02-24
SMT201700258T1 (it) 2017-07-18
HK1221466A1 (en) 2017-06-02
JP2019011364A (ja) 2019-01-24
RS58743B1 (sr) 2019-06-28
PT3527263T (pt) 2021-02-01
AR096330A1 (es) 2015-12-23
HRP20170795T1 (hr) 2017-08-25
KR20160019905A (ko) 2016-02-22
SI3786162T1 (sl) 2024-02-29
LT2997023T (lt) 2017-06-26
MY174788A (en) 2020-05-14
IL264409A (en) 2019-02-28
BR112015028501B1 (pt) 2022-11-01
MX373238B (es) 2020-05-08
UA117830C2 (uk) 2018-10-10
HRP20231048T1 (hr) 2023-12-22
ES2720073T3 (es) 2019-07-17
NZ753637A (en) 2020-11-27
WO2014186706A1 (en) 2014-11-20
IL282644A (en) 2021-06-30
KR102341908B1 (ko) 2021-12-23
JP2024105557A (ja) 2024-08-06
PT3786162T (pt) 2023-10-20
EA201592199A1 (ru) 2016-05-31
ES2845210T3 (es) 2021-07-26
ME02763B (me) 2018-01-20
PH12018502125A1 (en) 2019-03-25
KR20220127371A (ko) 2022-09-19
CY1121763T1 (el) 2020-07-31
SMT202500397T1 (it) 2025-11-10
CY1123756T1 (el) 2022-05-27
HRP20210119T1 (hr) 2021-03-05
JP2016519147A (ja) 2016-06-30
HK1245769B (en) 2020-02-07
MX2020004506A (es) 2021-08-09
ES3047826T3 (en) 2025-12-05
LT4275756T (lt) 2025-11-10
AU2022263454B2 (en) 2024-01-18
KR20240063187A (ko) 2024-05-10
DK4275756T3 (da) 2025-09-29
IL287313A (en) 2021-12-01
NZ713999A (en) 2020-11-27
EP4620528A2 (en) 2025-09-24
CR20150633A (es) 2016-04-05
EA202090291A2 (ru) 2020-05-31
SG11201509180WA (en) 2015-12-30
TR201905814T4 (tr) 2019-05-21
EP2997023B1 (en) 2017-03-22
HUE043573T2 (hu) 2019-08-28
FI4275756T3 (fi) 2025-10-20
TWI664176B (zh) 2019-07-01
KR20210120120A (ko) 2021-10-06
PL2997023T3 (pl) 2017-08-31
PH12015502563A1 (en) 2016-02-22

Similar Documents

Publication Publication Date Title
IL242453B (en) Bipyrazole derivatives as jak inhibitors
IL240863A0 (en) Amatoxin derivatives
LT2953944T (lt) Piridazinono amidų dariniai
ZA201506156B (en) Novel inhibitors
ZA201601333B (en) Oxoquinazolinyl-butanamide derivatives
IL240763B (en) The halopyrazoles as thrombin inhibitors
SG11201605189YA (en) Imidazopyrazinone derivatives